604 related articles for article (PubMed ID: 25759019)
21. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
22. Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.
Mohan SV; Chang AL
Semin Cutan Med Surg; 2014 Jun; 33(2):68-71. PubMed ID: 25085664
[TBL] [Abstract][Full Text] [Related]
23. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.
Sánchez-Danés A; Larsimont JC; Liagre M; Muñoz-Couselo E; Lapouge G; Brisebarre A; Dubois C; Suppa M; Sukumaran V; Del Marmol V; Tabernero J; Blanpain C
Nature; 2018 Oct; 562(7727):434-438. PubMed ID: 30297799
[TBL] [Abstract][Full Text] [Related]
24. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
25. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
Ighilahriz M; Benfodda M; Sharpe H; Soufir N; Mourah S; Dumaz N; Battistella M; Savina A; Bouquet F; Nikolaev S; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e422-e424. PubMed ID: 31187903
[No Abstract] [Full Text] [Related]
26. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
27. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
28. Relation between sonic hedgehog pathway gene polymorphisms and basal cell carcinoma development in the Polish population.
Lesiak A; Sobolewska-Sztychny D; Majak P; Sobjanek M; Wodz K; Sygut KP; Majsterek I; Wozniacka A; Narbutt J
Arch Dermatol Res; 2016 Jan; 308(1):39-47. PubMed ID: 26590974
[TBL] [Abstract][Full Text] [Related]
29. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.
Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE
Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
Von Hoff DD; LoRusso PM; Rudin CM; Reddy JC; Yauch RL; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Mackey HM; Lum BL; Darbonne WC; Marsters JC; de Sauvage FJ; Low JA
N Engl J Med; 2009 Sep; 361(12):1164-72. PubMed ID: 19726763
[TBL] [Abstract][Full Text] [Related]
31. [A new drug for basal cell carcinoma].
Witte F
Schweiz Monatsschr Zahnmed; 2013; 123(12):1104-6. PubMed ID: 24730087
[No Abstract] [Full Text] [Related]
32. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
33. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
[TBL] [Abstract][Full Text] [Related]
34. Sonic hedgehog pathway dysregulation in skin basal-cell carcinoma of a Polish population.
Lesiak A; Sobolewska-Sztychny D; Danilewicz M; Rogowski-Tylman M; Sysa-Jedrzejowska A; Sobjanek M; Olejniczak-Staruch I; Narbutt J
Folia Histochem Cytobiol; 2013; 51(3):219-24. PubMed ID: 24203628
[TBL] [Abstract][Full Text] [Related]
35. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors.
Zhu GA; Li AS; Chang AL
JAMA Dermatol; 2014 Aug; 150(8):877-9. PubMed ID: 24898076
[TBL] [Abstract][Full Text] [Related]
36. Vismodegib.
Meiss F; Zeiser R
Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
[TBL] [Abstract][Full Text] [Related]
37. Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice.
Khoo AB; Ali FR; Lear JT
Curr Opin Oncol; 2016 Mar; 28(2):180-4. PubMed ID: 26780190
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib: a review.
Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
[TBL] [Abstract][Full Text] [Related]
39. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
40. Expression of sonic hedgehog signal transducers, patched and smoothened, in human basal cell carcinoma.
Tojo M; Mori T; Kiyosawa H; Honma Y; Tanno Y; Kanazawa KY; Yokoya S; Kaneko F; Wanaka A
Pathol Int; 1999 Aug; 49(8):687-94. PubMed ID: 10504535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
